Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Aggregate index of systemic inflammation tied to increased fatty liver disease risk: insights from NHANES data.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: BioMed Central Country of Publication: England NLM ID: 100968547 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-230X (Electronic) Linking ISSN: 1471230X NLM ISO Abbreviation: BMC Gastroenterol Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : BioMed Central, [2001-
    • Subject Terms:
    • Abstract:
      Background: Fatty liver disease (FLD), characterized by hepatic lipid accumulation, impairs quality of life and can progress to cirrhosis and hepatocellular carcinoma, imposing a healthcare burden. This study investigates the association between the aggregate index of systemic inflammation (AISI) and FLD prevalence, evaluating AISI's potential as an early biomarker for risk assessment.
      Methods: Data were obtained from the National Health and Nutrition Examination Survey (NHANES) database, which encompasses the years 2017 through 2020. Participants were chosen based on the availability of controlled attenuation parameter (CAP) scores derived from transient elastography (TE), a technique utilized for assessing liver steatosis. The formula employed to compute the AISI is as follows: AISI = N × P × M / L, where N, P, M, and L refer to neutrophils, platelets, monocytes, and lymphocytes, respectively. Additionally, demographic, socioeconomic, dietary, and health-related information was gathered. Logistic regression models were utilized to pinpoint risk factors associated with FLD, and a nomogram was created to forecast FLD risk.
      Results: Of the 3,961 participants, 2,377 (60.0%) were diagnosed with FLD based on a CAP score ≥ 248 dB/m. Elevated AISI was significantly associated with FLD (P = 0.021). Other significant risk factors included sex, age, BMI, race, marital status, hypertension, and diabetes. The nomogram demonstrated excellent discriminatory performance with an AUC of 0.814 (95% CI: 0.800, 0.827) and good calibration.
      Conclusion: This study reveals a significant, independent association between elevated AISI and increased FLD risk in the U.S. population, even after adjusting for confounders. AISI demonstrated good discriminative performance for FLD, but its effect size suggests it should supplement, not replace, existing clinical risk assessment tools. AISI, a cost-effective biomarker, holds potential for enhancing FLD screening, particularly in resource-limited settings.
      (© 2025. The Author(s).)
    • Abstract:
      Declarations. Ethics approval and consent to participate: The NCHS research ethics review board approved the NHANES study involving human subjects, and participants provided written informed consent upon enrollment. The studies were carried out in compliance with local regulations and institutional guidelines.Participants gave written informed consent before joining the study. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.
    • References:
      Scand J Gastroenterol. 2022 Jul;57(7):872-877. (PMID: 35189786)
      Dig Dis Sci. 2023 Sep;68(9):3765-3773. (PMID: 37392337)
      Lipids Health Dis. 2023 Mar 29;22(1):44. (PMID: 36991386)
      Ther Adv Endocrinol Metab. 2024 Sep 25;15:20420188241274350. (PMID: 39350947)
      EMBO Mol Med. 2024 Aug;16(8):1901-1929. (PMID: 38977927)
      Int J Mol Sci. 2023 Oct 23;24(20):. (PMID: 37895168)
      Front Immunol. 2024 Feb 28;15:1337241. (PMID: 38481995)
      Cancers (Basel). 2022 Nov 09;14(22):. (PMID: 36428596)
      J Clin Med. 2021 May 10;10(9):. (PMID: 34068699)
      J Innate Immun. 2022;14(1):31-41. (PMID: 34515137)
      Clin Exp Med. 2025 Jan 15;25(1):39. (PMID: 39812894)
      Hepatology. 2021 Oct;74(4):2277-2286. (PMID: 33961302)
      Cell Signal. 2024 Aug;120:111229. (PMID: 38763181)
      Clin Res Hepatol Gastroenterol. 2022 Mar;46(3):101847. (PMID: 34920140)
      Wiley Interdiscip Rev RNA. 2024 Mar-Apr;15(2):e1840. (PMID: 38613185)
      Hepatology. 2016 Jul;64(1):73-84. (PMID: 26707365)
      Hepatology. 2019 Oct;70(4):1457-1469. (PMID: 30924946)
      JHEP Rep. 2023 Aug 11;5(11):100877. (PMID: 37869071)
      Diabetes Technol Ther. 2012 Feb;14(2):152-8. (PMID: 22149546)
      Front Immunol. 2024 Mar 27;15:1380476. (PMID: 38605957)
      Nutrients. 2023 Apr 12;15(8):. (PMID: 37111075)
      Am J Clin Pathol. 2007 Jun;127(6):954-60. (PMID: 17509993)
      Diabetes Res Clin Pract. 2024 Mar;209:111575. (PMID: 38346591)
      Sci Rep. 2021 Mar 4;11(1):5129. (PMID: 33664397)
      Int J Mol Sci. 2023 Nov 29;24(23):. (PMID: 38069218)
      Front Immunol. 2022 Sep 02;13:977485. (PMID: 36119080)
      J Inflamm Res. 2025 Feb 04;18:1623-1638. (PMID: 39925928)
      J Hepatol. 2017 May;66(5):1022-1030. (PMID: 28039099)
      Int J Mol Sci. 2023 Jun 02;24(11):. (PMID: 37298632)
      Dig Dis Sci. 2022 Apr;67(4):1389-1398. (PMID: 33788095)
      Cell Death Dis. 2020 May 18;11(5):379. (PMID: 32424179)
      Gastroenterol Rep (Oxf). 2024 Jun 24;12:goae069. (PMID: 38915345)
      BMC Gastroenterol. 2009 Feb 17;9:16. (PMID: 19222849)
      Hepatol Commun. 2022 Jun;6(6):1322-1335. (PMID: 35076162)
      Environ Health Perspect. 2024 Jan;132(1):17009. (PMID: 38285237)
      BMC Cardiovasc Disord. 2023 Dec 14;23(1):615. (PMID: 38097927)
      World J Hepatol. 2020 Apr 27;12(4):149-159. (PMID: 32685107)
      Hepatobiliary Surg Nutr. 2024 Feb 1;13(1):119-123. (PMID: 38322226)
    • Grant Information:
      zyyzdxk-2023165 the NATCM's Project for High-level Construction of Key TCM Disciplines in Minority Pharmacy (Zhuang Pharmacy); 2023GXNSFBA026188 the Guangxi Natural Science Foundation; GZXK-Z-20-60 the Guangxi Key Discipline of TCM (Zhuang medicine)
    • Contributed Indexing:
      Keywords: Aggregate index of systemic inflammation; Complete blood cell count-derived inflammatory indicator; Fatty liver disease; Inflammation; NHANES
    • Accession Number:
      0 (Biomarkers)
    • Publication Date:
      Date Created: 20250523 Date Completed: 20250524 Latest Revision: 20250526
    • Publication Date:
      20260130
    • Accession Number:
      PMC12101034
    • Accession Number:
      10.1186/s12876-025-03998-6
    • Accession Number:
      40410700